Europe Guillain-Barre Syndrome Market

Europe Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Report Id: KBV-21415 Publication Date: March-2024 Number of Pages: 118
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Europe Guillain-Barre Syndrome Market would witness market growth of 4.4% CAGR during the forecast period (2023-2030).

The Germany market dominated the Europe Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $57,999.6 Thousands by 2030. The UK market is exhibiting a CAGR of 3.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.2% during (2023 - 2030).

Europe Guillain-Barre Syndrome Market

The applications of the Guillain-Barre syndrome market encompass various aspects of diagnosis, treatment, supportive care, and rehabilitation, all aimed at improving patient outcomes and quality of life. Accurate and timely diagnosis of GBS is essential for initiating appropriate treatment and managing the condition effectively.

Moreover, nerve conduction studies (NCS) measure the electrical signal intensity and speed as they travel along peripheral nerves to assess nerve function. Abnormalities in nerve conduction velocities and amplitudes indicate nerve damage characteristic of GBS.

Likewise, specialized neurology clinics in Spain, such as Hospital Clínic de Barcelona or Hospital Universitario La Paz in Madrid, are dedicated to diagnosing and managing neurological disorders, including GBS. Therefore, the market is growing due to the expansion of the healthcare industry and the development of rehabilitation facilities in the region.

Free Valuable Insights: The Global Guillain-Barre Syndrome Market will Hit USD 852.2 Million by 2030, at a CAGR of 4.6%

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • F.Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • PTC, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company

Europe Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others

By Route Of Administration

  • Parenteral
  • Oral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo